The New Challenges In The Pharmaceutical Industry, What Strategy To Face Them? Sanofi Experience.
Main Article Content
Abstract
This research discusses the pharmaceutical industry new challenges, like the slowdown of market growth, showdown of biosimilars and advanced technologies, and tries to highlight the main axes of the facing strategy, by taking the experience of the French company Sanofi as example. Ending by giving some ideas about what could the Algerian pharmaceutical companies get from this experience. As results, there is trending towards biotechnological companies which makes the acquisition or merger with them very important. Second, collaborations are necessary to provide better health solutions. Third, the inevitability of digitalizing the sector and keeping good relationship with investors and society.
Article Details
References
] [ Keith D.Tait : « Chapter 79_Pharmaceutical Industry », Encyclopaedia Of Occupational Health And Safety, The International Labour Office ILO, 4th Edition, http://www.ilocis.org/documents/chpt79e.htm#JD_Ch79_1 (21/03/2019)
] [ Ministère De L’industrie, De La Petites Et Moyennes Entreprise Et De La Promotion De L’investissement (2011): « Rapport Sectoriel N°1: Industrie Pharmaceutique »; Algérie, P 3.
] [ Monique Ellis (2019): “Opportunities And Challenges Foe Pharmaceutical Industry In 2019”, https://www.proclinical.com/blogs/2019-2/opportunities-challenges-for-pharmaceutical-industry-in-2019 (25/03/2019)
] [ https://www.infinitiresearch.com/thoughts/pharmaceutical-industry-challenges (25/03/2019)
] [ Cecil Nick (2012): "The US Biosimilars Act: Challenges Facing Regulatory Approval", Pharm Med, V 26, issue 3, p 146.
] [ https://www.infinitiresearch.com/thoughts/pharmaceutical-industry-challenges (25/03/2019)
] [ Nisha K Karim (2012): « Challenges And Opportunities For Pharma Industry », http://pharmabiz.com/ArticleDetails.aspx?aid=69654&sid=9 (25/03/2019)
Monique Ellis, op.cit.
] [ https://successstory.com/companies/sanofi (25/03/2019)
] [ Idem.
] [ “Sanofi-Aventis To Sign Deal To Build Flu Vaccine Plant In China" (23 November 2007), AFX News, Forbes.
] [ https://www.sanofi.com/en/about-us/sanofi-at-a-glance (26/03/2019)
] [ Börse Frankfurt (Frankfurt Stock Exchange) (2019): Stock Market Quotes, Charts And News", Www.Boerse-Frankfurt. (25/03/2019)
] [https://en.wikipedia.org/wiki/Sanofi#cite_note-5 (26/03/2019)
] [ Idem, (28/03/2019)
] [https://successstory.com/companies/sanofi, op.cit. (28/03/2019)
] [ Sanofi-Synthélabo Form 20F for the Fiscal Year ended 31 December 2002, https://www.sec.gov/Archives/edgar/data/1121404/000095010903003612/d20f.htm#tx363_10 (27/03/2019)
] [ https://successstory.com/companies/sanofi, op.cit. (27/03/2019)
] [ “Sanofi pasteur Awarded $97 Million HHS Contract to Accelerate Cell-Culture Pandemic Influenza Vaccine Development"(4 April 2005), https://web.archive.org/web/20050425220406/http://www.presseportal.de/story.htx?nr=664301&ressort=7 (27/03/2019)
] [ Hannah Blake (Feb 25th, 2013): « A History Of Sanofi », https://pharmaphorum.com/articles/a_history_of-_sanofi/ (28/03/2019)
] [ Mennella, Noelle (6 May 2011). "Sanofi Changes Name, Pace Of Acquisitions To Slow", Reuters, https://www.reuters.com/article/sanofi/sanofi-changes-name-pace-of-acquisitions-to-slow-idUSLDE74521Z20110506 (27/03/2019)
] [ Chris V. Nicholson (16 February 2011): “Sanofi Agrees to Buy Genzyme for $20.1 Billion”, the New York Times' Dealbook, https://dealbook.nytimes.com/2011/02/16/sanofi-agrees-to-buy-genzyme-for-at-least-20-1-billion/ (28/03/2019)
] [https://en.wikipedia.org/wiki/Genzyme (28/03/2019)
] [ https://successstory.com/companies/sanofi , op.cit. (28/03/2019)
] [ Sanofi Aventis (2007): “The Half-Year Financial Report”, p 26.
] [ https://www.sanofi.com/en/about-us (28/03/2019)
] [ https://fr.wikipedia.org/wiki/Sanofi_R%26D#cite_note-5 (28/03/2019)
] [ Sanofi (2018): “In Business For Life-Partnering To Advance Global Health”, p 1.
] [ Ibid, p 18.
] [ Sanofi (2015): “Sanofi Sets Out Strategic Roadmap For Long-Term Growth”, p 2.
] [ Idem.
] [ Idem.
] [ Douglas Hawks : “Mature Markets : Definition And Examples”, https://study.com/academy/lesson/mature-markets-definition-examples.html (28/03/2019)
] [ Sanofi (2018): “In Business For Life-Partnering To Advance Global Health”, op.cit, p 9.
] [ https://en.wikipedia.org/wiki/Emerging_market#cite_note-1 (29/03/2019)
] [ Kemberly Amadeo (Jan 17, 2019): “What Are Emerging Markets? Five Defining Characteristics”, https://www.thebalance.com/what-are-emerging-markets-3305927 (29/03/2019)
] [ Sanofi (2018): “In Business For Life-Partnering To Advance Global Health”, op.cit, p 9.
] [ Idem.
] [ Ibid, p13.
] [ Sanofi (March 24, 2017): “Sanofi Launches Digital Clinical Trials To Improve Recruitment And Reduce Trial Time”, https://mediaroom.sanofi.com/en/articles/2017/sanofi-launches-digital-clinical-trials-to-improve-recruitment-and-reduce-trial-times/ (29/03/2019)
] [ Sanofi (July 12, 2018): “Factory Of The Future”, https://www.sanofi.com/en/science-and-innovation/factory-of-the-future (30/03/2019)
Watch Sanofi Future Factory, https://www.youtube-nocookie.com/embed/2sZU9sxHXVk?rel=0 (30/03/2019)
] [ Sanofi (July 12, 2018): “Factory of the future”, op.cit. https://www.sanofi.com/en/science-and-innovation/factory-of-the-future (30/03/2019)
] [Sanofi: “Corporate Citizenship”, https://www.sanofi.com/en/our-responsibility/corporate-citizenship (30/03/2019)
] [ Sanofi: “Environment Compact”, https://www.sanofi.com/en/our-responsibility/environmental-impact (30/03/2019)
] [ Sanofi: “Ethics And Transparency”, https://www.sanofi.com/en/our-responsibility/ethics-and-transparency (30/03/2019)
] [ Sanofi (Feb 7, 2019): “Investors”, https://www.sanofi.com/en/investors (30/03/2019)
] [ Sanofi: “stock charts” , https://www.sanofi.com/en/investors/sanofi-share-and-adrs/stock-chart/ (30/03/2019)
] [ Sanofi (Feb 06, 2019): “Dividends”, https://www.sanofi.com/en/investors/sanofi-share-and-adrs/dividends (30/03/2019)
] [ Idem.